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Two pairs of proven monozygotic twins discordant
for familial amyloid neuropathy (FAP) TTR Met
30
Miguel Munar-Qués, Jorge L Pedrosa, Teresa Coelho, Leonor Gusma˜o, Raquel Seruca,
António Amorim, Jorge Sequeiros
Abstract
Twin studies are an important tool in
medical genetics for the evaluation of the
relative roles of genetic and non-genetic
factors in several diseases. Familial amy-
loidotic polyneuropathy type I (FAP-I),
TTR Met 30, was present in two sets of
proven monozygotic (MZ) twins, one from
Majorca and the other from Portugal.
Monozygosity was established by analysis
of DNA polymorphisms. Both pairs were
discordant for age at onset and some
clinical manifestations of FAP-I. We re-
viewed the diVerences in age at onset and
clinical features in both sets and in two
other pairs of presumed MZ twins with
FAP-I and compared them with those in
MZ twin pairs with other Mendelian
disorders, such as neurofibromatosis type
1, Huntington’s disease, facioscapulo-
humeral muscular dystrophy, and myo-
tonic dystrophy. We conclude that, in
addition to the postulated modifying
genes, there must be a significant contri-
bution from non-genetic factors to the
phenotypic variability of FAP-I (age at
onset and clinical expression), either be-
cause of enviromental diVerences or sto-
chastic events during (or after) the
twinning process.
(J Med Genet 1999;36:629–632)
Keywords: hereditary amyloidosis; discordant MZ
twins; non-genetic factors; stochastic process
FAP type I (FAP-I) is an autosomal dominant
systemic amyloidosis mainly involving the
peripheral nerves. It was first described in
Portugal1 and later on in many other countries.
The areas with the highest prevalence are Por-
tugal, Japan, Sweden, Brazil, and the island of
Majorca (Spain).2 The genetic defect of FAP-I3
is a single point mutation in the gene encoding
the plasma protein transthyretin (TTR), lo-
cated on chomosome 18; for this reason, the
modern nomenclature of FAP-I is FAP fol-
lowed by the mutant TTR.
So far more than 60 amyloidogenic TTR
mutations have been reported. TTR Met 30 is
by far the most common and the only one
identified in all Majorcan patients and in virtu-
ally all patients from Portugal, Japan, Sweden,
and Brazil. In the majority of TTR mutations
there is a substitution of one amino acid for
another in the 127 chain; in a few families, two
amino acids have been substituted in that
chain, and in one family only there is a deletion
of one amino acid.
No clinical diVerences have been found in
these areas, though there is considerable
variability in the age at onset; on average this
was higher in the Majorcan patients (46.7
years) than in Portugal (33.5 years),4 Japan
(35.6 years),5 or Brazil (32.4 years),6 but lower
than in Sweden (56.7 years).4 As a conse-
quence, the number of old asymptomatic
carriers is much greater in Sweden, intermedi-
ate in Majorca, and very small in Portugal.
We present here two sets of MZ twins with
FAP-I, one from Majorca and the other from
Portugal. To our knowledge, these are the first
two pairs of proven MZ twins with FAP TTR
Met 30.
Case reports
TWIN SET 1
This set consisted of white male twins (J and
G) born in Majorca in 1931, who were
thought, from birth, to be identical, though no
zygosity studies had been performed. They
were reared together until the age of 26, when
twin G got married; thereafter, they always
lived in the same neighbourhood. They had
similar social and economic levels and their
jobs were both related to car maintenance and
repair (twin J was a panel beater and twin G
worked in a service station). Neither of them
smoked or drank alcohol regularly. There was
a striking physical resemblance, despite twin G
having hypotrophy of his right arm, as a result
of a brachial paralysis after delivery. One of us
(MMQ) knew both men before they devel-
oped FAP-I and could verify their resem-
blance.
Twin G was followed by us from the age of
57 years, by which time his twin J had already
died. Clinical information on twin J was kindly
provided by several physicians. The clinical
diagnosis on twin J was confirmed by demon-
stration of amyloid deposits in an intestinal
biopsy and on twin G through detection of
TTRMet 30 in serum. There was no history of
FAP-I in their ancestors. One son of twin J
became aVected at the age of 27 and two years
later underwent orthotopic liver transplanta-
tion (OLT) with good results.
The clinical picture was discordant in the
twins. Twin J had onset of FAP-I at the age of
38, whereas twin G had onset at 50 years of
age, two years after twin J had died. In both, the
initial symptom was a sensorimotor syndrome,
but this was more aggressive in twin G as he
was confined to a wheelchair seven years later,
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whereas twin J was still walking with two sticks
when he died 12 years after onset. Twin J had
diarrhoea with encopresis, but twin G suVered
from severe constipation. Both had urinary
problems owing to a neurogenic bladder and
impotence; twin J had renal involvement with
proteinuria and progressive renal failure seven
years after onset, whereas twin G developed
similar symptoms nine years after his first
symptoms. Only twin G showed amyloid
deposits in both eyes nine years after onset and
for this reason he underwent bilateral vitrec-
tomy. Death occurred at the age of 48 in twin J
(after 10 years disease duration), while twin G
died at the age of 63 (a disease duration of 13
years).
Study of monozygosity in this set of twins
was a challenge, because we had only old par-
aYn blocks of intestinal biopsies from both
patients, performed on twin J in 1976 and on
twin G in 1991. DNA was extracted from the
blocks for analysis of DNA polymorphisms.
The posterior probability of monozygosity was
99.03% (table 1).
TWIN SET 2
This set consists of white male twins (twins J
and A) born in Portugal in 1959, who were also
thought to be identical. They were reared
together until the age of 21, when twin J got
married; thereafter, they had no significant
environmental diVerences that could be de-
tected and their professions, after university
graduation, were the same. There was a strong
family history of FAP-I. At the age of 25 they
were diagnosed as carriers by detection of TTR
Met 30 in serum. Both had a sacrococcygeal
cyst, for which they were operated on in the
same year.
Twin A had onset of FAP-I at the age of 30,
whereas twin J had onset at 34 years of age.
The clinical picture was also discordant. The
initial symptom in twin A was a very aggressive
sensorimotor syndrome with early involve-
ment of the upper limbs, while in twin J it was
a severe loss of weight. Later on, twin A had
cardiac rhythm disturbances, orthostatic hy-
potension, occasional episodes of diarrhoea,
and neurotrophic ulcers on both feet, but twin
J had only a minor sensorimotor syndrome
and gastrectasia. Twin A underwent OLT at
the age of 34 but he died seven months later,
after successive peritoneal complications;
twin J underwent a successful OLT at the age
of 35.
Analysis of DNA polymorphisms was per-
formed after extraction of DNA, from paraYn
blocks of necropsy material in twin A and from
a fresh blood sample in twin J. The posterior
probability of monozygosity was 99.99% (table
1).
Discussion
CLINICAL DISCORDANCE IN MZ TWINS WITH
SPORADIC OR CHROMOSOMAL DISORDERS
Twin studies are an important tool in medical
genetics in the evaluation of the relative roles of
genetic and non-genetic factors in several
diseases. In particular, the occurrence of MZ
twins clinically discordant for a presumably
hereditary disorder may be crucial to resolve
diagnosis7 or to determine its true aetiology8 or
pattern of inheritance.9 Some chromosomal
abnormalities that have occurred postzygoti-
cally, such as undetected mosaicism or small
deletions below the cytogenetic resolution
level, could explain discordant MZ twins with
usually sporadic disorders, such as
Brachmann-de Lange,10 Rubinstein-Taybi,11
McCune-Albright,12 Beckwith-Wiedemann,13 14
Williams,15 and other syndromes.
CLINICAL DISCORDANCE IN MZ TWINS WITH
MENDELIAN DISORDERS
The high correlation in clinical variation of
neurofibromatosis type 1 (NF1) in MZ twins,
as compared to other relatives, suggests an
important role of modifying genes.16 Also, in
Huntington’s disease (HD), age at onset seems
to have a major genetic component; 12 twin
sets, proven or presumed to be MZ, either had
onset in the same year or less than three years
apart. However, clinical presentation was
rather diVerent in two pairs of MZ twins with
HD17; in one additional pair of proven MZ
twins, reared apart from birth, age at onset and
clinical evolution were remarkably similar.18 In
myotonic dystrophy (DM), MZ twins were
discordant for lens opacities and other pheno-
typic findings.19 DiVerent clinical expression in
MZ twins with DM may be explained by a
variable number of CTG repeats,20 owing to
diVerent patterns of somatic mosaicism. In a
pair of MZ twins, one was severely aVected
with facioscapulohumeral muscular dystrophy,
while the other was almost asymptomatic.21 No
evidence for somatic mosaicism of a postzy-
gotic, pre-twinning mutation was found; it was
thus hypothesised that an anti-rabies vaccine,
received by the more severely aVected twin,
might have triggered an inflammatory immune
response, which enhanced muscle fibre dam-
age.
CLINICAL DISCORDANCE IN MZ TWINS WITH FAP-I
Besides our two pairs of proven MZ twins, two
other sets of presumed MZ twins are known to
us: one pair of female twins, born in Indonesia
in 1937,22 and one pair born in Sweden in
Table 1 Estimation of posterior probability of monozygosity
Locus Genotype Twinning index (TI) Twinning probability (TP) (%)
Twin set 1 (Majorcan)
CD4 6-10 2.760 73.40
FES 12-13 3.770 79.04
TP53 6-8 2.545 71.79
TPO 11-11 1.250 55.56
Total 51.081 98.08
Considering sex: TI=51.081×2; TP=102.162 Posterior probability of MZ=99.03%
Twin set 2 (Portuguese)
D3S1358 15-17 3.158 75.95
D5S818 11-13 3.090 75.55
D8S1179 15 1.330 57.08
D13S317 11-12 2.741 73.27
D21S11 30-32.2 3.602 78.27
F13A 5-6 2.882 74.24
MBPB 11 1.216 54.87
TH01 7-9.3 2.958 74.74
TP53 6-8 2.545 71.79
VWA 14-17 3.041 75.25
Total 10 280.279 99.99
Considering sex: TI=10280.279×2; TP=99.99 Posterior probability of MZ=99.99%
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1940.23 The main data from these four sets of
MZ twins with FAP-I are summarised in table
2.
In the latter two sets, there is also clear
discordance in clinical expression.The Indone-
sian twins had a very strong family history of
FAP-I and were diagnosed by detection of
amyloid deposits on rectal biopsies. Onset was
four years apart; twin 1 (onset at the age of 33)
had a more severe peripheral neuropathy, but
also a multiple cranial neuropathy, as well as
cardiac and renal failure, not present in twin 2
(who had onset at the age of 29). Environmen-
tal diVerences or similarities were not reported.
The Swedish pair was diagnosed by DNA
analysis; FAP-I was present in their paternal
uncle. Onset in twin 1 was at the age of 48 with
a progressive sensorimotor neuropathy, gastro-
intestinal symptoms, and orthostatic hypoten-
sion. Recently, at the age of 54, he received a
successful OLT, while twin 2 was still asympto-
matic.
The simultaneous occurrence of a sacrococ-
cygeal cyst in both Portuguese MZ twins is
noteworthy, constrasting with their relative dis-
cordance for age at onset and clinical symp-
toms of FAP-I.
GENETIC MODIFIERS, AGE AT ONSET, AND
CLINICAL SEVERITY
The importance of genetic modifiers in age at
onset and clinical expression has been postu-
lated in NF1,16 HD,18 and DM,19 as well as in
FAP-I.24 25 However, the margin for clinical
variation existing in HD indicates that this is
only partly influenced by the genome.17 Over-
all, there were significant diVerences within
each of the four (three male) pairs of MZ twins,
both in clinical severity and age at onset (which
may be as much apart as 12 years), clearly
showing that the TTR mutation and its genetic
modifiers are not the only determinants of age
dependent penetrance and variable expressivity
of FAP-I. Other, non-genetic, factors (that is,
either undetected environmental factors or
stochastic events at the molecular/cellular level
occurring before or during the twinning
process) must be operating.
THE POSSIBLE EFFECT OF STOCHASTIC,
POSTZYGOTIC EVENTS
In diseases with knownMendelian inheritance,
diVerences between MZ twins in terms of age
at onset, clinical picture, and severity are
usually taken as an indicator of the interaction
of the mutant gene with environmental factors;
this is, however, influenced by strong observa-
tional biases. While most environmental diVer-
ences between MZ twins will remain undetec-
ted, the occasional finding of a single difference
is too often followed by a hasty conclusion of a
causal eVect.
Not all non-genetic factors, however, need to
be environmental. Non-random or skewed
lyonisation, for instance, will explain discord-
ance for chromosomal disorders and also some
instances of discordant female MZ twins for X
linked Mendelian disorders26 27; the same may
apply for autosomal diseases with modifying
loci on the X chromosome. Also, somatic
mosaicism for aneuploidies, including small
deletions, or for expanded trinucleotide re-
peats, may explain diVerences between (female
or male) MZ twins with chromosomal disor-
ders or those resulting from unstable dynamic
mutations (such as HD or DM). In classical
mutations, such as FAP TTRMet 30, different
patterns of somatic mosaicism for (nuclear)
modifying genes or diVerent distributions of
mitochondrial modifiers could, in theory,
explain diVerent expressions of the mutant
gene in either twin.
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